In Vitro Specific Binding of Shiga Toxin 1 and 2 by TAK-751S (Gb3 analog)

Takeda, Tae; Yoshino, Ken‐ichi; Adachi, Eriko; Yamagata, Kyohko; Uchida, Hiroshi; Okonogi, Kenji; Iizawa, Yuji

doi:10.11150/kansenshogakuzasshi1970.72.924

Cited by 3 publications

(3 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our previous report (26), the stable Stx binding activity of Synsorb Pk was confirmed after incubation of processed foods, retail fresh vegetables and fruits, or antibiotics such as fosfomycin, kanamycin and norfloxacin for 1 hr at 37 C. In this study, we observed that the effect of heat on Synsorb Pk was an important factor to be examined with caution. Stx l binding activity was stable to the effect of boiling for 10 min.…”

Section: N Vitro Assessment Of Synsorb Pk 335mentioning

confidence: 82%

See 1 more Smart Citation

In Vitro Assessment of a Chemically Synthesized Shiga Toxin Receptor Analog Attached to Chromosorb P (Synsorb Pk) as a Specific Absorbing Agent of Shiga Toxin 1 and 2

Takeda¹,

Yoshino²,

Adachi³

et al. 1999

Microbiology and Immunology

Self Cite

View full text Add to dashboard Cite

A synthetic analog of Shiga toxin (Stx) receptor (Synsorb Pk) was quantitatively assessed to determine whether it can protect human renal adenocarcinoma cells (ACHN cells) from the cytotoxicity of Stx1 and Stx2 by coincubation experiments. Coincubation of 100 and 20 ng of Stx1 and Stx2 with 50 mg of Synsorb Pk for 1 hr at 37 C in 1 ml of Eagle's Minimum Essential Medium supplemented with 1% (v/v) nonessential amino acid and 10% (v/v) fetal calf serum protected 50% of the cells from the cytotoxic effect. Chromosorb P, an inert matrix control, did not absorb the Stxs at all. Heat‐treatment (boiled for 10 min) to Synsorb Pk caused a 50% decrease in Stx2‐binding activity, but did not effect the Stx1 binding. Further, Stxs bound to Synsorb Pk could be demonstrated. When 20 mg of Synsorb Pk was coincubated for 30 min at 37 C in 1 ml of phosphate‐buffered saline with 1 and 10 ng or more of Stx1 or Stx2, respectively, the toxins could be detected on the surface when the bound toxins on Synsorb Pk were used as the solid phase in enzyme immunoassay. The amount of 100 ng/ml of both Stx1 and Stx2 appeared to saturate 20 mg/ml of Synsorb Pk after coincubating for 30 min at 37 C. While assessing the Stxs' binding activity to Synsorb Pk, it was demonstrated that Stx1 had a higher affinity to Pk trisaccharide than Stx2. These observations provide useful information on the effectiveness of Synsorb Pk to trap and eliminate free Stxs produced in the gut of patients infected by Stx‐producing Escherichia coli, and to prevent the progression of hemorrhagic colitis to hemolytic uremic syndrome.

show abstract

Section: N Vitro Assessment Of Synsorb Pk 335mentioning

confidence: 82%

“…Information of the clinical trials prompted us to evaluate the potential of Synsorb Pk for use in patients with STEC infections in Japan. We have already confirmed and reported the in vitro-specific Stx binding of Synsorb Pk under various conditions (26). The objective of this study is to assess its potential as a therapeutic agent for disease caused by STEC.…”

mentioning

confidence: 84%

In Vitro Assessment of a Chemically Synthesized Shiga Toxin Receptor Analog Attached to Chromosorb P (Synsorb Pk) as a Specific Absorbing Agent of Shiga Toxin 1 and 2

Takeda¹,

Yoshino²,

Adachi³

et al. 1999

Microbiology and Immunology

Self Cite

View full text Add to dashboard Cite

show abstract

“…[4][5][6][7][8][9] Appropriate therapeutic approaches, such as antibiotics, for treating EHEC infection remain the subject of discussion because the risk of HUS is increased by verotoxin (VT) released from disrupted EHEC. 5,[9][10][11][12][13][14][15][16] Numerous treatments have been investigated to inhibit the progress of VT-induced HUS; for example, Synsorb-Pk, [17][18][19] a VT adsorbent, and anti-VT humanized monoclonal antibody. 20,21 Furthermore, the efficacy of early treatment with fosfomycin (FOM) in preventing HUS has been reported.…”

Section: Introductionmentioning

confidence: 99%

Neutralizing activity of bovine colostral antibody against verotoxin derived from enterohemorrhagic Escherichia coli O157:H7 in mice

Kuribayashi

Seita

Fukuyama

et al. 2006

Journal of Infection and Chemotherapy

View full text Add to dashboard Cite

Potential for using antibiotics combined with a Shiga toxin-absorbing agent for treating 0157:H7 Escherichia coli infections

Mulvey¹,

Rafter²,

Armstrong³

2002

Can. J. Chem.

View full text Add to dashboard Cite

Antibiotics are not recommended for treating O157:H7 Escherichia coli infections because they may promote Shiga toxin (Stx) release from these bacteria. This could increase the risk of Stx-mediated complications in patients suffering from such infections. Here, we observed increased cell-free Stx in E. coli O157:H7 cultures exposed to sub-inhibitory concentrations of several antibiotics. Synsorb-Pk, an agent with a high affinity for Stx, absorbed Stx activity from the antibiotic-treated cultures. These data suggest certain antibiotics, given in combination with an orally administered Stx-binding agent, may be useful in treating O157:H7 E. coli infections.Key words: Shiga toxin, Synsorb, Escherichia coli, O157:H7, antibiotics, therapy.

show abstract

In Vitro Specific Binding of Shiga Toxin 1 and 2 by TAK-751S (Gb3 analog)

Cited by 3 publications

References 14 publications

In Vitro Assessment of a Chemically Synthesized Shiga Toxin Receptor Analog Attached to Chromosorb P (Synsorb Pk) as a Specific Absorbing Agent of Shiga Toxin 1 and 2

In Vitro Assessment of a Chemically Synthesized Shiga Toxin Receptor Analog Attached to Chromosorb P (Synsorb Pk) as a Specific Absorbing Agent of Shiga Toxin 1 and 2

Neutralizing activity of bovine colostral antibody against verotoxin derived from enterohemorrhagic Escherichia coli O157:H7 in mice

Potential for using antibiotics combined with a Shiga toxin-absorbing agent for treating 0157:H7 Escherichia coli infections

Contact Info

Product

Resources

About